Detection of Human Papilloma Virus in Papanicolaou (Pap) Smears

• US 20060275784A1
• Filed: 04/01/2006
• Published: 12/07/2006
• Est. Priority Date: 10/26/1999
• Status: Abandoned Application

• Current Assignee: Ventana Medical Systems Incorporated (Roche Holding AG)
• Original Assignee: Ventana Medical Systems Incorporated (Roche Holding AG)
• Inventors: Light, Elizabeth S., Nuovo, Gerard J., Krein, Peter M., Pestic-Dragovich, Lidija, Jones, Tobin
• Application Number:
  US11/278,410
• Publication Number:
  US 20060275784A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C12Q 1/6806 Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay C12Q1/6804 takes precedence
• CPC Class Codes: C12Q 1/70 involving virus or bacteriophage immunoassay for viruses G01N33/56983
• CPC Class Codes: C12Q 1/708 for papilloma
• CPC Class Codes: C12Q 2527/119 pH
• CPC Class Codes: C12Q 2527/125 Specific component of sample, medium or buffer

Abstract

Methods and reagents for detecting high-risk human papilloma virus (HPV) DNA types in cells on a Pap smear which indicates the patient is at higher risk for cancer are described. The method differentiates high-risk from low-risk HPV DNA in cells, which indicates the patient'"'"'s risk for cancer.

Claims

1. A method for detecting target DNA in a cell or tissue sample comprising:

(a) exposing the cell or tissue sample to a cell conditioning buffer comprising a first buffer component and a second buffer component, wherein;

(i) the first buffer component comprises a chelating agent and has a pH of about 6;

(ii) the second buffer component comprises an ionic detergent;

(b) exposing the cell or tissue sample to a probe that is capable of specifically hybridizing to the target DNA in the cell or tissue sample, and;

(c) detecting the presence or absence of hybridization of the probe in the cell or tissue sample.

2. The method of claim 1, wherein the first buffer component comprises 0.01 M citrate and has a pH of about 6.

3. The method of claim 1, wherein the first buffer component is Cell Conditioning Solution (CC2).

4. The method of claim 1, wherein the second buffer component is EZ Prep.

5. The method of claim 1, wherein the first buffer component and the second buffer component are mixed at a ratio of 1:

1.

6. The method of claim 1, wherein the first buffer component and the second buffer component are mixed at a ratio of 2:

1.

7. The method of claim 1, wherein the first buffer component and the second buffer component are mixed at a ratio of 3:

1.

8. The method of claim 1, wherein the cell or tissue sample is exposed to the cell conditioning buffer for between 4 and 32 minutes.

9. The method of claim 1, wherein the cell or tissue sample is exposed to the cell conditioning buffer a temperature of between 90°

C. and 95°

C.

10. The method of claim 1, wherein the cell conditioning buffer is removed after step (a) and the cell or tissue sample is exposed to fresh cell conditioning buffer before exposing the cell or tissue sample to the probe in step (b).

11. The method of claim 1, further comprising pretreating the cell or tissue sample with a protease.

12. The method of claim 1, further comprising destaining and/or deparaffining the cell or tissue sample.

13. A method for detecting human papilloma virus (HPV) DNA in a cell or tissue sample which indicates the patient providing the cell or tissue sample is at risk for cancer comprising:

(a) exposing the cell or tissue sample to a cell conditioning buffer comprising a first buffer component and a second buffer component, wherein;

(i) the first buffer component comprises a chelating agent and has a pH of about 6;

(ii) the second buffer component comprises an ionic detergent;

(b) exposing the cell or tissue sample to a reagent comprising at least one genomic HPV DNA probe that is capable of specifically hybridizing to high-risk HPV DNA but not to low-risk HPV DNA under hybridization conditions, and;

(c) detecting the presence or absence of hybridization of the genomic HPV DNA probe in the cell or tissue sample.

14. The method of claim 13, wherein the first buffer component comprises 0.01 M citrate and has a pH of about 6.

15. The method of claim 13, wherein the first buffer component is Cell Conditioning Solution (CC2).

16. The method of claim 13, wherein the second buffer component is EZ Prep.

17. The method of claim 13, wherein the first buffer component and the second buffer component are mixed at a ratio of 1:

1.

18. The method of claim 13, wherein the first buffer component and the second buffer component are mixed at a ratio of 2:

1.

19. The method of claim 13, wherein the first buffer component and the second buffer component are mixed at a ratio of 3:

1.

20. The method of claim 13, wherein the cell or tissue sample is exposed to the cell conditioning buffer for between 4 and 32 minutes.

21. The method of claim 13, wherein the cell or tissue sample is exposed to the cell conditioning buffer a temperature of between 90°

C. and 95°

C.

22. The method of claim 13, wherein the cell conditioning buffer is removed after step (a) and the cell or tissue sample is exposed to fresh cell conditioning buffer before exposing the cell or tissue sample to the reagent comprising at least one genomic HPV DNA probe in step (b).

23. The method of claim 13, further comprising pretreating the cell or tissue sample with a protease.

24. The method of claim 13, further comprising destaining and/or deparaffining the cell or tissue sample.

25. The method of claim 13, wherein the cell sample is cervical cells taken from a patient.